Pharmacology of dopamine agonists in the treatment of Parkinson's disease

Neurology
Peter Jenner

Abstract

There is now increasing use of dopamine agonists as effective early monotherapy in the treatment of Parkinson's disease (PD). Dopamine agonists can induce an antiparkinsonian effect through actions on either D(1)-like or D(2)-like dopamine receptors, and the multiple receptor subtypes present in the brain may provide further opportunities to improve the treatment of PD. Functional interactions exist between D(1)- and D(2)-like receptors, and adaptive changes occur after denervation and repeated administration of a dopamine agonist. Long-acting dopamine agonists produce a lower incidence of dyskinesia than levodopa (L-dopa) when they are used as monotherapy in either PD or in drug-naïve 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primates. Continuous dopaminergic stimulation appears less likely to prime basal ganglia for involuntary movements compared with drugs, such as L-dopa, that produce pulsatile stimulation. However, once priming has occurred, dopamine agonists produce dyskinesia identical to that of L-dopa. Continuous administration of long-acting dopamine agonists may reverse the priming process initiated by L-dopa, markedly decreasing dyskinesia intensity with a minimal loss of antiparkinsonian activity,...Continue Reading

Citations

Jul 20, 2005·Pharmaceutical Research·Teun M PostMeindert Danhof
Aug 29, 2002·Acta Psychiatrica Scandinavica·D Aarsland, J L Cummings
Apr 30, 2009·Science Signaling·Marcelo P CobaSeth G N Grant
Jun 19, 2009·Journal of Neurophysiology·Xin FengChristy L Ludlow
Aug 2, 2002·Current Opinion in Neurology·Ron Tintner, Joseph Jankovic
Apr 18, 2008·Expert Review of Neurotherapeutics·Mitsutoshi Yamamoto, Anthony H V Schapira
Dec 10, 2015·Expert Opinion on Drug Safety·Roberto CeravoloUbaldo Bonuccelli
Dec 3, 2008·Expert Opinion on Emerging Drugs·Karl Strecker, Johannes Schwarz
Jul 25, 2012·Experimental Gerontology·Xin FengStephen B Kritchevsky
Jul 5, 2011·Neurología : publicación oficial de la Sociedad Española de Neurología·A Alonso CánovasJ C Martínez Castrillo
Nov 29, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M Steiger
Apr 14, 2011·British Journal of Pharmacology·Susan Duty, Peter Jenner
Mar 4, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Juliana BronzovaUNKNOWN Bruegel Study Group
Oct 14, 2014·Frontiers in Cellular Neuroscience·Francisca MeyerMichel M M Verheij
Feb 7, 2016·Chemical Biology & Drug Design·Xinli DuanMing Lei
Aug 26, 2016·Expert Opinion on Pharmacotherapy·Fabrizio StocchiChiara Fossati
Feb 22, 2017·Chemistry : a European Journal·Antoni Llopis-LorenteReynaldo Villalonga
Apr 1, 2003·Annals of Neurology·Anthony H V Schapira, C Warren Olanow
May 13, 2003·Nature Medicine·Erwan BézardPierre Sokoloff
Feb 10, 2006·Expert Review of Neurotherapeutics·Ubaldo Bonuccelli, Nicola Pavese
Mar 23, 2007·Expert Opinion on Pharmacotherapy·Johan Samanta, Robert A Hauser
Jan 16, 2013·Pharmacological Reviews·Philippe HuotJonathan M Brotchie
Dec 5, 2002·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H V Schapira
Apr 3, 2019·Drugs & Aging·Martin KlietzGünter U Höglinger
Nov 6, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Maria PapathanouAndrew C McCreary
Apr 11, 2019·Drugs·Margherita TortiFabrizio Stocchi
Jun 27, 2020·Neurobiology of Disease·Haruo NishijimaMasahiko Tomiyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.